Abbott increases investment in SpectRx:
This article was originally published in Clinica
Abbott Laboratories has increased its shareholding in the non-invasive glucose monitor developer, SpectRx, of Norcross, Georgia, by buying $2.75 million in preferred shares with a further $2.5 million commitment in January under the same terms. The revised agreement for the continuous monitoring device, presently in prototype form, gives Abbott exclusive worldwide marketing rights. SpectRx gets new milestones and will get a royalty on disposables when the product is eventually launched.
You may also be interested in...
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.
Sawai’s sales increased on the back of a good performance from recently-launched products in the first nine months of its financial year. However, given the competitive environment the Japanese company is continuing to stick to its full-year forecasts.